Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or Unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

A clinical practice guideline for women with human epidermal growth factor receptor 2–negative (HER2-negative) or unknown advanced breast cancer. The guideline examines first-line treatment options including the benefits of single agent versus combination therapy, specifically the role of bevacizumab. Outcomes of interest include slowed disease progression, modestly improved survival, and increased communication concerning end of life planning.